KK-LC-1 as a therapeutic target to eliminate ALDH

Humans Triple Negative Breast Neoplasms / metabolism Breast / pathology Neoplastic Stem Cells / metabolism Cell Line, Tumor

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
05 05 2023
Historique:
received: 12 09 2022
accepted: 14 04 2023
medline: 8 5 2023
pubmed: 6 5 2023
entrez: 5 5 2023
Statut: epublish

Résumé

Failure to achieve complete elimination of triple negative breast cancer (TNBC) stem cells after adjuvant therapy is associated with poor outcomes. Aldehyde dehydrogenase 1 (ALDH1) is a marker of breast cancer stem cells (BCSCs), and its enzymatic activity regulates tumor stemness. Identifying upstream targets to control ALDH

Identifiants

DOI: 10.1038/s41467-023-38097-1 PMID: 37147285 PMC: PMC10163259
pubmed: 37147285
doi: 10.1038/s41467-023-38097-1
pii: 10.1038/s41467-023-38097-1
pmc: PMC10163259
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2602

Informations de copyright

© 2023. The Author(s).

Références

Cancer Cell. 2018 Dec 10;34(6):893-905.e8
pubmed: 30537512
Cells. 2021 Jun 07;10(6):
pubmed: 34200285
Int J Oncol. 2020 Dec;57(6):1245-1261
pubmed: 33174058
Breast Care (Basel). 2021 Feb;16(1):6-15
pubmed: 33716627
Front Oncol. 2019 Dec 06;9:1311
pubmed: 31867270
Nat Rev Cancer. 2012 Jan 12;12(2):133-43
pubmed: 22237392
Sci Rep. 2018 Apr 17;8(1):6131
pubmed: 29666402
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Oncotarget. 2019 Apr 2;10(26):2515-2529
pubmed: 31069014
Future Med Chem. 2011 Dec;3(16):2021-38
pubmed: 22098351
Exp Mol Pathol. 2016 Feb;100(1):177-83
pubmed: 26721716
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Onco Targets Ther. 2018 Apr 17;11:2185-2193
pubmed: 29713187
BMC Cancer. 2021 Mar 12;21(1):267
pubmed: 33711953
EMBO Mol Med. 2019 Oct;11(10):e9930
pubmed: 31476112
Nature. 2021 Jan;589(7842):448-455
pubmed: 33328637
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Dev Cell. 2010 Oct 19;19(4):491-505
pubmed: 20951342
Cancer Res. 2006 May 1;66(9):4922-8
pubmed: 16651449
Mol Cell Biochem. 2022 Dec;477(12):2689-2702
pubmed: 35606602
Cell. 1982 Nov;31(1):99-109
pubmed: 6297757
Environ Toxicol. 2021 Nov;36(11):2333-2341
pubmed: 34390292
Cancer Res. 2012 Sep 1;72(17):4574-86
pubmed: 22751464
Genes Dev. 2013 Feb 15;27(4):355-71
pubmed: 23431053
Stem Cells Transl Med. 2019 Jan;8(1):75-81
pubmed: 30328686
Oncogene. 2011 Jan 20;30(3):287-300
pubmed: 20838375
J Comput Chem. 2013 Jan 5;34(1):67-75
pubmed: 22961860
Oncogene. 2017 Mar 2;36(9):1265-1275
pubmed: 27593935
J Cancer. 2016 Jan 01;7(2):167-73
pubmed: 26819640
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
J Exp Clin Cancer Res. 2016 May 25;35:84
pubmed: 27225481
Stem Cell Reports. 2013 Dec 27;2(1):78-91
pubmed: 24511467
Front Oncol. 2022 Jan 19;11:791696
pubmed: 35127497
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D187-91
pubmed: 16381842
Cancer Res. 2021 Dec 1;81(23):5919-5934
pubmed: 34580061
Nat Genet. 2013 Mar;45(3):253-61
pubmed: 23354438
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
World J Gastroenterol. 2017 Dec 14;23(46):8200-8206
pubmed: 29290656
Nucleic Acids Res. 2022 Jan 7;50(D1):D439-D444
pubmed: 34791371
Breast Cancer Res. 2020 Jun 9;22(1):61
pubmed: 32517735
Mol Carcinog. 2017 Mar;56(3):1127-1136
pubmed: 27753148
Oncotarget. 2015 Sep 22;6(28):25356-67
pubmed: 26327325
Oncogene. 2015 Feb 5;34(6):681-90
pubmed: 24531710
Adv Sci (Weinh). 2019 Nov 13;7(1):1901728
pubmed: 31921558
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Expert Rev Mol Med. 2015 Jul 02;17:e14
pubmed: 26136233
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
Nat Rev Mol Cell Biol. 2012 Dec;13(12):767-79
pubmed: 23151663
Clin Transl Med. 2014 Dec;3(1):32
pubmed: 26932376
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8
pubmed: 23726034
Cancers (Basel). 2019 Apr 08;11(4):
pubmed: 30965654
Cancer Cell. 2018 Apr 9;33(4):690-705.e9
pubmed: 29622464
Mol Oncol. 2018 Apr;12(4):423-440
pubmed: 29316250
Cell Prolif. 2019 May;52(3):e12581
pubmed: 30895661
Cell Death Dis. 2018 Feb 7;9(2):192
pubmed: 29416006
J Transl Med. 2019 Apr 8;17(1):116
pubmed: 30961610
Nat Commun. 2022 Mar 16;13(1):1371
pubmed: 35296660
Cancer Res. 2019 Oct 1;79(19):4965-4977
pubmed: 31387918
Cancers (Basel). 2014 Sep 05;6(3):1769-92
pubmed: 25198391
Expert Rev Anticancer Ther. 2019 Jun;19(6):447-454
pubmed: 31082272
J Med Internet Res. 2021 Jul 26;23(7):e27633
pubmed: 34309564
Matrix Biol. 2019 Aug;81:107-121
pubmed: 30502484
In Vivo. 2017 May-Jun;31(3):403-407
pubmed: 28438869

Auteurs

Jiawen Bu (J)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Yixiao Zhang (Y)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Sijin Wu (S)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.
Shenzhen Jingtai Technology Co., Ltd. (XtalPi), International Biomedical Industrial Park (Phase II) 3F, 2 Hongliu Rd, Futian District, 16023, Shenzhen, China.

Haonan Li (H)

School of Bioengineering, Dalian University of Technology, 116023, Dalian, China.

Lisha Sun (L)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Yang Liu (Y)

School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, 110016, Shenyang, China.

Xudong Zhu (X)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Xinbo Qiao (X)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Qingtian Ma (Q)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Chao Liu (C)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Nan Niu (N)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.
ORCID: 0000-0002-8206-941X

Jinqi Xue (J)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Guanglei Chen (G)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.

Yongliang Yang (Y)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China. everbright99@foxmail.com.
School of Bioengineering, Dalian University of Technology, 116023, Dalian, China. everbright99@foxmail.com.
ORCID: 0000-0003-0449-0599

Caigang Liu (C)

Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China. liucg@sj-hospital.org.
ORCID: 0000-0003-2083-235X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › KK-LC-1 as a therapeutic target to eliminate ALDH
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tumeurs du sein triple-négatives › KK-LC-1 as a therapeutic target to eliminate ALDH
questionsmedicales.fr › Régions du corps › Région mammaire › KK-LC-1 as a therapeutic target to eliminate ALDH
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches tumorales › KK-LC-1 as a therapeutic target to eliminate ALDH
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › KK-LC-1 as a therapeutic target to eliminate ALDH